CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.15 USD | +0.42% |
|
-19.66% | +386.39% |
| 05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
| 05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CANDEL THERAPEUTICS, INC. | Other Biotechnology & Medical Research | +0.42% | -19.66% | +386.39% | +373.51% | - | 213M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CADL Stock
- Charts Candel Therapeutics, Inc.
- Comparison Chart
